IRIS
DEMARZO, MARIA GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.083
Totale 1.083
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 1.083
Totale 1.083
Salva come PNG Salva come JPEG
Città #
Genova 558
Genoa 220
Vado Ligure 167
Rapallo 134
Bordighera 4
Totale 1.083
Salva come PNG Salva come JPEG
Nome #
High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease 123
Improvement in Waldenstrom’s macroglobulinemia after successful treatment of HCV with direct-acting antivirals 101
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 89
A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease 89
Reproducibility and transportability of the absence of incremental infectious adverse events in patients with higher anti-TNF drug levels 86
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients 85
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation 72
Concerns related to COVID-19 pandemic among patients with Inflammatory Bowel Disease, and its influence on patients management 71
Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio 61
Review article – esophageal reflux hypersensitivity: Non-GERD or still GERD? 56
Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques 53
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD 46
Elevated adherence to vaccination against SARS-CoV-2 among patients with Inflammatory Bowel Disease 43
Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment 40
An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders 30
Reduction of fecal calprotectin levels induced by a short-course of Escherichia coli Nissle is associated with a lower likelihood of disease flares in patients with ulcerative colitis in clinical remission 29
Pharmacological management of gastro-esophageal reflux disease: An update of the state-of-the-art 29
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator 24
Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission 15
Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies 6
Totale 1.148
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.691
article - articoli 5.601
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.292
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020189 0 0 0 0 0 30 32 25 23 44 23 12
2020/2021131 6 15 4 19 7 5 4 21 7 20 12 11
2021/2022186 7 4 9 11 8 21 10 38 19 21 12 26
2022/2023180 23 22 1 5 21 20 1 28 25 2 27 5
2023/2024173 3 18 1 25 18 31 11 1 7 5 25 28
2024/2025185 24 22 21 15 51 52 0 0 0 0 0 0
Totale 1.148